Patent · US Active

Bispecific antibodies against CD3 and CD20

US10544220B2 · kind B2 · utility

9Cited by
0References
12Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJan 8, 2016
Grant dateJan 28, 2020
Priority date
Expiry dateJan 8, 2036

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/94
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.